98%
921
2 minutes
20
Purpose: To investigate the awareness and the spread of ChatGPT and its possible role in both scientific research and clinical practice among the young radiation oncologists (RO).
Material And Methods: An anonymous, online survey via Google Forms (including 24 questions) was distributed among young (< 40 years old) ROs in Italy through the yAIRO network, from March 15, 2024, to 31, 2024. These ROs were officially registered with yAIRO in 2023. We particularly focused on the emerging use of ChatGPT and its future perspectives in clinical practice.
Results: A total of 76 young physicians answered the survey. Seventy-three participants declared to be familiar with ChatGPT, and 71.1% of the surveyed physicians have already used ChatGPT. Thirty-one (40.8%) participants strongly agreed that AI has the potential to change the medical landscape in the future. Additionally, 79.1% of respondents agreed that AI will be mainly successful in research processes such as literature review and drafting articles/protocols. The belief in ChatGPT's potential results in direct use in daily practice in 43.4% of the cases, with mainly a fair grade of satisfaction (43.2%). A large part of participants (69.7%) believes in the implementation of ChatGPT into clinical practice, even though 53.9% fear an overall negative impact.
Conclusions: The results of the present survey clearly highlight the attitude of young Italian ROs toward the implementation of ChatGPT into clinical and academic RO practice. ChatGPT is considered a valuable and effective tool that can ease current and future workflows.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11547-024-01945-1 | DOI Listing |
Breast Cancer Res Treat
September 2025
Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA.
Purpose: Black women with hormone receptor-positive (HR +) breast cancer are twice as likely as White women to have weakly HR + tumors (1-10% positive cells). Patients with weakly HR + tumors are less frequently prescribed ET and have 60% higher mortality than strongly HR + tumors (> 10% positive cells). We evaluated factors associated with ET prescription and self-reported use among Black women with HR + breast cancer.
View Article and Find Full Text PDFRep Pract Oncol Radiother
August 2025
Department of Oncology and Radiotherapy, University Hospital in Pilsen, Pilsen, Czech Republic.
In the recent years, the clinical stage where the cancer has spread beyond the primary site, but has not yet metastasised extensively, and which is known as oligometastatic disease (OMD), has become an object of interest to radiation oncologists. OMD is a kind of an "umbrella term" for a variety of clinical situations. This review focuses on the role of radiotherapy (RT) in the treatment of oligometastatic non-small cell lung cancer (OM-NSCLC).
View Article and Find Full Text PDFPract Radiat Oncol
September 2025
Department of Radiation Oncology, Institut Bergonié, Bordeaux, France; Centre de Radiothérapie Charlebourg, La Défense, Groupe Amethyst, 65, avenue Foch, 92250 La Garenne-Colombes, France.
Purpose: Urinary toxicity following radical prostatectomy (RP) and postoperative radiotherapy (RT) includes urinary incontinence and vesicourethral anastomosis (VUA) strictures. With the increasing use of stereotactic body radiotherapy (SBRT), dose-escalation, and reirradiation within the prostate bed (PB), standardization of the definition of urinary organs at risk (OARs) in the post-RP setting is needed. This works aims to provide a comprehensive review of the anatomical and physiopathological changes occurring after RP, as well as to provide a consensus on urinary OARs delineation for prostate cancer (PCa) EBRT in the post-RP setting.
View Article and Find Full Text PDFJ Cancer Educ
September 2025
Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, FL, USA.
Understanding when and how patients encounter cancer treatment misinformation (CTM) is essential for developing innovative strategies to combat its spread. However, a major challenge in CTM research is the lack of a reliable and valid tool to assess exposure to misinformation. This study aimed to evaluate patients' exposure to CTM through the exposure to cancer treatment misinformation (ECTM) survey.
View Article and Find Full Text PDFCan J Urol
August 2025
Department of Radiation Oncology, Baskent University Faculty of Medicine, Ankara, 06490, Turkiye.
Background: Intermediate-risk prostate cancer (IR-PC) represents a heterogeneous group requiring nuanced treatment approaches, and recent advancements in radiotherapy (RT), androgen deprivation therapy (ADT), and prostate-specific membrane antigen positron emission tomography (PSMA-PET/CT) imaging have prompted growing interest in personalized, risk-adapted management strategies. This study by the Turkish Society for Radiation Oncology aims to examine radiation oncologists' practices in managing IR-PC, focusing on RT and imaging modalities to identify trends for personalized treatments.
Methods: A cross-sectional survey was conducted among Turkish radiation oncologists treating at least 50 prostate cancer (PC) cases annually.